IL2 and neoplasm: Seeger et al. discovered that glycosides deaminate (GD2) are tumor-associated antigens that are highly expressed in all neuroblastoma cells and enhanced anti-tumor immunotherapy with immunotherapy using chimeric anti-GD2 monoclonal antibodies in combination with IL-2 and GM-CSF.